Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.Financial_Report.xls
10-K - Arch Therapeutics, Inc.g6510.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R13.htm
EX-32.1 - Arch Therapeutics, Inc.ex32-1.txt
EX-31.1 - Arch Therapeutics, Inc.ex31-1.txt
XML - IDEA: XBRL DOCUMENT - Arch Therapeutics, Inc.R20.htm
v2.4.0.6
Note 5 - Income Taxes
12 Months Ended
Sep. 30, 2012
Notes  
Note 5 - Income Taxes

Note 5 - Income Taxes

 

As of September 30, 2012 the Company had net operating loss carry forwards of approximately $(41,648) that may be available to reduce future years’ taxable income through 2017.  Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a full valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. 

 

The components of the deferred tax asset, the statutory tax rate, the effective tax rate and the elected amount of the valuation allowance are indicated below:

                                               

                                                 From September 16, 2009 (Inception)

                                                          To September 30, 2012

                                                                 

Net Operating Loss                                     $41,648

Statutory Tax Rate                                           34%

Deferred Tax Asset                                        $14,160

Valuation Allowance                                     $(7,100)

Net Deferred Tax Asset                                  $ 0